Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 4, 2013, Pages 493-498

  Terakawa, Tomoaki ^a   Miyake, Hideaki ^a   Kusuda, Yuji ^a   Fujisawa, Masato ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Progression free survival; Renal cell carcinoma; Sunitinib; VEGFR 2

Indexed keywords

C REACTIVE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; STAT3 PROTEIN; SUNITINIB; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURGERY; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY METASTASIS; MALE; NEPHRECTOMY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REPEATED DRUG DOSE; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; NEPHRECTOMY; PROGNOSIS; PYRROLES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84876739783     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2011.02.012     Document Type: Article

References (23)

1. Rini B.I., Rathmell W.K., Godley P. Renal cell carcinoma. Curr Opin Oncol 2008, 20:300-306.
2. Parton M., Gore M., Eisen T. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J Clin Oncol 2006, 24:5584-5592.
3. Miyake H., Kurahashi T., Takenaka A., et al. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma. Urol Oncol 2009, 27:598-603.
4. Bellmunt J., Montagut C., Albiol S., et al. Present strategies in the treatment of metastatic renal cell carcinoma: An update on molecular targeting agents. BJU Int 2007, 99:274-280.
5. Lane B.R., Rini B.I., Novick A.C., et al. Targeted molecular therapy for renal cell carcinoma. Urology 2007, 69:3-10.
6. Fyfe G., Fisher R.I., Rosenberg S.A., et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995, 13:688-696.
7. Motzer R.J., Bacik J., Murphy B.A., et al. Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002, 20:289-296.
8. Casamassima A., Picciariello M., Quaranta M., et al. C-reactive protein: A biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J Urol 2005, 173:52-55.
9. Reeves D.J., Liu C.Y. Treatment of metastatic renal cell carcinoma. Cancer Chemother Pharmacol 2009, 64:11-25.
10. Motzer R.J., Hutson T.E., Tomczak P., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:3584-3590.
11. Kurahashi T., Muramaki M., Yamanaka K., et al. Expression of the secreted form of clusterin protein in renal cell carcinoma as a predictor of disease extension. BJU Int 2005, 96:895-899.
12. Miyake H., Muramaki M., Kurahashi T., et al. Expression of potential molecular markers in prostate cancer: Correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Urol Oncol 2010, 28:145-151.
13. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003, 9:327-337.
14. Hutson T.E., Figlin R.A., Kuhn J.G., et al. Targeted therapies for metastatic renal cell carcinoma: An overview of toxicity and dosing strategies. Oncologist 2008, 13:1084-1096.
15. Gore M.E., Szczylik C., Porta C., et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: An expanded-access trial. Lancet Oncol 2009, 10:757-763.
16. Uemura H., Shinohara N., Yuasa T., et al. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: Insights into the treatment, efficacy and safety. Jpn J Clin Oncol 2010, 40:194-202.
17. Choueiri T.K., Regan M.M., Rosenberg J.E., et al. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU Int 2010, 106:772-778.
18. Perez-Gracia J.L., Prior C., Guillén-Grima F., et al. Identification of TNF-&;α and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array. Br J Cancer 2009, 101:1876-1883.
19. Kusuda Y., Miyake H., Behnsawy H.M., et al. Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens. Urol Oncol 2013, 31:42-50.
20. Rini B.I., Michaelson M.D., Rosenberg J.E., et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008, 26:3743-3748.
21. Kontovinis L.F., Papazisis K.T., Touplikioti P., et al. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: Clinical outcomes and plasma angiogenesis markers. BMC Cancer 2009, 9:82.
22. Deprimo S.E., Bello C.L., Smeraglia J., et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: Modulation of VEGF and VEGF-related proteins. J Transl Med 2007, 5:32.
23. Porta C., Paglino C., De Amici M., et al. Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib. Kidney Int 2010, 77:809-815.